<SEC-DOCUMENT>0001144204-16-086776.txt : 20160309
<SEC-HEADER>0001144204-16-086776.hdr.sgml : 20160309
<ACCEPTANCE-DATETIME>20160309083026
ACCESSION NUMBER:		0001144204-16-086776
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20160309
FILED AS OF DATE:		20160309
DATE AS OF CHANGE:		20160309

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36000
		FILM NUMBER:		161493439

	BUSINESS ADDRESS:	
		STREET 1:		XTL BIOPHARMACEUTICALS LTD
		STREET 2:		C/O ALSTON & BIRD LLP, 90 PARK AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		972 9 955 7080

	MAIL ADDRESS:	
		STREET 1:		85 MEDINAT HAYEHUDIM ST.
		STREET 2:		PITUACH, PO BOX 4033
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			46140
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v433827_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: center; text-indent: 0">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: center; margin: 0; text-indent: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 1pt solid; margin: 0; width: 100%; text-align: center; text-indent: 0">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0; text-align: center; text-indent: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 12pt"><B>Form 6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0">For the month of March, 2016</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0">Commission File Number: <B>000-36000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 12pt"><B><U>XTL
Biopharmaceuticals Ltd.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0">(Translation of registrant&rsquo;s name
into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><B>5 HaCharoshet St.,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><B>Raanana 4365603</B><BR>
<B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Israel&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0">Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form
20-F&nbsp;</FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><B>Incorporation by Reference: This Form
6-K of XTL Biopharmaceuticals Ltd. is hereby incorporated by reference into the registration statements on Form S-8 (File No.
333-148085, File No. 333-148754 and File No. 333-154795) and Form F-3 (File No. 333-194338).</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="text-transform: uppercase"><IMG SRC="xtlbiologo.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt; text-transform: uppercase"><B>LUPUS
THOUGHT LEADER daphna paran, md, named medical <BR>
director of xtl biopharmaceuticals </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 11pt"><B>World
renowned expert in the treatment of lupus with over 60 published articles <BR>
and extensive clinical trial experience</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>RAANANA,
Israel</B></FONT><B> - (March 9, 2016) &ndash; <FONT STYLE="color: Blue"><U>XTL Biopharmaceuticals Ltd.</U></FONT> (NASDAQ: XTLB,
TASE: XTLB.TA) </B>(&ldquo;XTL&rdquo; or the &ldquo;Company&rdquo;), a clinical-stage biopharmaceutical company developing its
lead product for the treatment of lupus, today announced the appointment of Dr. Daphna Paran, an internal medicine and rheumatology
specialist, as Medical Director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Dr. Paran has significant experience
in the treatment of lupus patients, has published extensively on the subject, and has been involved in several clinical studies
in the search for viable treatment options for this difficult disease,&rdquo; said Josh Levine, CEO of XTL. &ldquo;We are excited
to welcome her aboard as our Medical Director as we enter the next phase of developing our lead drug candidate hCDR1 for the treatment
of systemic lupus erythematosus (SLE). Having received encouraging feedback from the U.S. Food and Drug Administration on our proposed
clinical trial, we are now completing the Phase II protocol design with Dr. Paran&rsquo;s guidance and anticipate initiating the
trial in the second half of 2016.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dr. Paran has over 20 years of rheumatology
expertise with a focus on lupus. She is a senior lecturer at Tel Aviv University, the head of the lupus clinic, head of the rheumatology
day care unit and the deputy head of the Department of Rheumatology at the Tel Aviv Medical Center (Ichilov Hospital). She completed
her medical studies at Ben Gurion University, trained in lupus and the antiphospholipid syndrome at the lupus unit, Rayne Institute,
St. Thomas' Hospital in London and has published or co-authored over 60 articles in the field of lupus and rheumatology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;I am privileged to join the team
as Medical Director of XTL to lend my experience to the advancement of what I believe to be a very promising lupus drug candidate,&rdquo;
stated Dr. Paran. &ldquo;hCDR1 showed very promising data in the prior Phase 2b trial. If we are able to duplicate these results
utilizing well defined primary endpoints in our next clinical study we could have a promising solution to a largely unmet medical
need. I and the rest of the medical community in this field are eagerly waiting to learn the efficacy of this drug in the upcoming
trial.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>About hCDR1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hCDR1
is a novel compound with a unique mechanism of action and has clinical data on over 400 patients in three clinical studies. The
drug has a favorable safety profile, is well tolerated by patients and has demonstrated efficacy in at least one clinically meaningful
endpoint.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For more information please see a peer
reviewed article in Lupus Science and Medicine journal (<FONT STYLE="color: Blue"><U>http://lupus.bmj.com/content/2/1/e000104.full</U></FONT>).
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 93%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XTL Biopharmaceuticals Ltd.</FONT></TD>
    <TD STYLE="width: 7%; font-size: 10pt; text-align: center">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 93%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 Hacharoshet Street, Raanana, 43656, Israel</FONT></TD>
    <TD STYLE="width: 7%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 1</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel: +972 9 955 7080; email: <FONT STYLE="color: blue"><U>ir@xtlbio.com</U></FONT> </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="xtlbiologo.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About Systemic Lupus Erythematosus (SLE)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lupus is a chronic autoimmune disease involving
many systems in the human body, including joints, kidneys, central nervous system, heart, hematological system and others. The
biologic basis of the disease is a defect in the immune (defense) system, leading to production of self (auto) antibodies, attacking
the normal organs and causing irreversible damage. According to the Lupus Foundation of America, at least 1.5 million Americans
have the disease (more than 5 million worldwide) with more than 16,000 new cases diagnosed each year. The majority of patients
are women of childbearing years. There has been only one drug approved by the FDA in the last 50 years and recently two of the
few drugs in advanced development did not meet their primary endpoints in Phase 3 trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 0.75pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>About XTL Biopharmaceuticals Ltd.
(XTL)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">XTL Biopharmaceuticals
Ltd., is a&nbsp;clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune
diseases including lupus. The Company&rsquo;s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of
systemic lupus erythematosus (SLE). There currently is no effective treatment on the market for SLE. hCDR1 has robust clinical
data in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than&nbsp;40 peer
reviewed scientific journals. Based on encouraging safety and efficacy data&nbsp;shown in a completed Phase 2 study, the Company
expects to initiate a Phase 2 trial in 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">XTL is&nbsp;traded
on the Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA). XTL shares are included in the following
indices: Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Tech Index.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 0.75pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>For further information, please contact:</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investor Relations, XTL Biopharmaceuticals
Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tel: +972 9 955 7080</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email: <FONT STYLE="color: Blue"><U>ir@xtlbio.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Blue"><U>www.xtlbio.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">========================================================================================================</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 93%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XTL Biopharmaceuticals Ltd.</FONT></TD>
    <TD STYLE="width: 7%; font-size: 10pt; text-align: center">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 93%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 Hacharoshet Street, Raanana, 43656, Israel</FONT></TD>
    <TD STYLE="width: 7%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 2</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel: +972 9 955 7080; email: <FONT STYLE="color: blue"><U>ir@xtlbio.com</U></FONT> </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="xtlbiologo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Cautionary Statement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release may contain forward-looking
statements, about XTL&rsquo;s expectations, beliefs or intentions regarding, among other things, its product development efforts,
business, financial condition, results of operations, strategies or prospects. In addition, from time to time, XTL or its representatives
have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use
of forward-looking words such as &quot;believe,&quot; &quot;expect,&quot; &quot;intend,&quot; &quot;plan,&quot; &quot;may,&quot;
&quot;should&quot; or &quot;anticipate&quot; or their negatives or other variations of these words or other comparable words or
by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may
be included in, but are not limited to, various filings made by XTL with the U.S. Securities and Exchange Commission, press releases
or oral statements made by or with the approval of one of XTL&rsquo;s authorized executive officers. Forward-looking statements
relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements
relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause
XTL&rsquo;s actual results to differ materially from any future results expressed or implied by the forward-looking statements.
Many factors could cause XTL&rsquo;s actual activities or results to differ materially from the activities and results anticipated
in such forward-looking statements, including, but not limited to, the factors summarized in XTL&rsquo;s filings with the SEC and
in its periodic filings with the TASE. In addition, XTL operates in an industry sector where securities values are highly volatile
and may be influenced by economic and other factors beyond its control. XTL does not undertake any obligation to publicly update
these forward-looking statements, whether as a result of new information, future events or otherwise. Please see the risk factors
associated with an investment in our ADSs or ordinary shares which are included in our Registration Statement on Form F-1 as filed
with the U.S. Securities and Exchange Commission on December 31, 2015.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 93%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XTL Biopharmaceuticals Ltd.</FONT></TD>
    <TD STYLE="width: 7%; font-size: 10pt; text-align: center">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 93%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 Hacharoshet Street, Raanana, 43656, Israel</FONT></TD>
    <TD STYLE="width: 7%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 3</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel: +972 9 955 7080; email: <FONT STYLE="color: blue"><U>ir@xtlbio.com</U></FONT> </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; padding-top: 0">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 0; padding-left: 0; padding-top: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>XTL BIOPHARMACEUTICALS LTD.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; padding-top: 0">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 0; padding-left: 0; padding-top: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; padding-top: 0">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 0; padding-left: 0; padding-top: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; padding-top: 0">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 0; padding-left: 0; padding-top: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; padding-top: 0; width: 50%">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; padding-top: 0; width: 3%">By:</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; padding-top: 0; width: 24%; border-bottom: Black 1pt solid">/s/ Josh Levine</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; padding-top: 0; width: 23%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; padding-top: 0">Date: March
9, 2016</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; padding-top: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0; padding-left: 0; padding-top: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Josh Levine</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; padding-top: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; padding-top: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0; padding-left: 0; padding-top: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>xtlbiologo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 xtlbiologo.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !% .4# 2(  A$! Q$!_\0
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MA'PVEJMLNG6\D;$JPDMHF#A$P00 @'R E>?E8!L'&*^-/^"?WQ,T7XD_L_\
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M8\X K\B/^"='Q!U;P%\?K_P--<S26/C33M=TO5+-CF-KK0HKF:.Z VLIE?:
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M -?S_P#&']GKP'\8].;3?%>@Z5KUFTBS&SU.QMKRT$ZX7[1]GGC=//""-/-
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MS*L3)T)86*I0RVKB9N*6*G%\U2.(:37NWBN;2QY/BMX45O$?%8'$T,THY;+
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M.G'XK+DB]*;E&[/\W_\ MKQ&H^76/%2ABSX74-9QN=BS9 =0#DGC^$84!0
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M+VZOQ]JU_4H)=0UO48TCBA>X9 $M83)N;RX2,F.,+"N<[&.2?HWX;?LO>"/
MD4,=IIUG:)$,I%:6T,8R&1ER44';\O?CH!S7TH^E6HLFLH8TB4P^2A55!
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MI=3ATV"._FFN.)99+E5#M)(HQ(P/S_3(/T-J.AV.I6LEK=V\31M$(=VP,^P
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M% PP/0?E2T44 ! /!&1Z&D  Z #Z "BB@!:*** $P,YP,^N!G\^M+110 4$
M]0#]>:** $P/0<<C@<'UHP/0?E110 8'H/R%&!Z#\A110 8'H/R%+110 A53
MU4'Z@4$ C! (]"./RHHH 7 ]/;\/2BBB@ HHHH 3 SG STS@9QZ9I<#&,#&,
98[8],>E%% ";5'  QZ8%+110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
